[1]
Schaller MD, Borgman CA, Cobb BS, Vines RR, Reynolds AB, Parsons JT. pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions. Proc Natl Acad Sci USA 1992; 89: 5192-6.
[2]
Ilić D, Furuta Y, Kanazawa S, et al. Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature 1995; 377: 539-44.
[3]
Romer LH, McLean N, Turner CE, Burridge K. Tyrosine kinase activity, cytoskeletal organization, and motility in human vascular endothelial cells. Mol Biol Cell 1994; 5: 349-61.
[4]
Kim I, Kim HG, Moon SO, et al. Angiopoietin-1 induces endothelial cell sprouting through the activation of focal adhesion kinase and plasmin secretion. Circ Res 2000; 86: 952-9.
[5]
Li W, Lee J, Vikis HG, et al. Activation of FAK and Src are receptor-proximal events required for netrin signaling. Nat Neurosci 2004; 7: 1213-21.
[6]
Chacón MR, Navarro AI, Cuesto G, et al. Focal adhesion kinase regulates actin nucleation and neuronal filopodia formation during axonal growth. Development 2012; 139: 3200-10.
[7]
Hungerford JE, Compton MT, Matter ML, Hoffstrom BG, Otey CA. Inhibition of pp125FAK in cultured fibroblasts results in apoptosis. J Cell Biol 1996; 135: 1383-90.
[8]
Frisch SM, Vuori K, Ruoslahti E, Chan-Hui PY. Control of adhesion-dependent cell survival by focal adhesion kinase. J Cell Biol 1996; 134: 793-9.
[9]
Sood AK, Coffin JE, Schneider GB, et al. Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion. Am J Pathol 2004; 165: 1087-95.
[10]
Corsi JM, Rouer E, Girault JA, Enslen H. Organization and post-transcriptional processing of focal adhesion kinase gene. BMC Genomics 2006; 7: 198.
[11]
Grigera PR, Jeffery ED, Martin KH, Shabanowitz J, Hunt DF, Parsons JT. FAK phosphorylation sites mapped by mass spectrometry. J Cell Sci 2005; 118: 4931-5.
[12]
Kadaré G, Gervasi N, Brami-Cherrier K, et al. Conformational dynamics of the focal adhesion targeting domain control specific functions of focal adhesion kinase in cells. J Biol Chem 2015; 290(1): 478-91.
[13]
Deramaudt TB, Dujardin D, Noulet F, et al. Altering FAK-paxillin interactions reduces adhesion, migration and invasion processes. PLoS One 2014; 9(3): e92059.
[14]
Lawson C, Lim S, Uryu XL, Calderwood DA, Schlaepfer DD. FAK promotes recruitment of talin to nascent adhesions to control cell motility. J Cell Biol 2012; 196(2): 223-32.
[15]
Ceccarelli DFJ, Song HK, Poy F, Schaller MD, Eck MJ. Crystal structure of the FERM domain of focal adhesion kinase. J Biol Chem 2006; 281: 252-9.
[16]
Dunty JM, Gabarra-Niecko V, King ML, Ceccarelli DFJ, Eck MJ, Schaller MD. FERM domain interaction promotes FAK signaling. Mol Cell Biol 2004; 24: 5353-68.
[17]
Ho B, Olson G, Figel S, Gelman I, Cance WG, Golubovskaya VM. Nanog increases Focal Adhesion Kinase (FAK) promoter activity and expression and directly binds to FAK protein to be phosphorylated. J Biol Chem 2012; 287: 18656-73.
[18]
Cheng N, Li Y, Han Z-G. Argonaute2 promotes tumor metastasis by way of up-regulating focal adhesion kinase expression in hepatocellular carcinoma. Hepatology 2013; 57: 1906-18.
[19]
Li S, Huang X, Zhang D, et al. Requirement of PEA3 for transcriptional activation of FAK gene in tumor metastasis. PLoS One 2013; 8: e79336.
[20]
Kong X, Li G, Yuan Y, et al. MicroRNA-7 inhibits epithelial-to-mesenchymal transition and metastasis of breast cancer cells via targeting FAK expression. PLoS One 2012; 7: e41523.
[21]
Cance WG, Golubovskaya VM. Focal adhesion kinase versus p53: apoptosis or survival? Sci Signal 2008; 1(20): pe22.
[22]
You D, Xin J, Volk A, et al. FAK mediates a compensatory survival signal parallel to PI3K-AKT in PTEN-Null T-ALL cells. Cell Reports 2015; 10(12): 2056-69.
[23]
Golubovskaya VM, Cance WG. Focal adhesion kinase and p53 signaling in cancer cells. Int Rev Cytol 2007; 263(7): 103-53.
[24]
Sulzmaier FJ, Jean C, Schlaepfer DD. FAK in cancer: mechanistic findings and clinical applications. Nat Rev Cancer 2014; 14(9): 598-610.
[25]
Ward KK, Tancioni I, Lawson C, et al. Inhibition of Focal Adhesion Kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression. Clin Exp Metastasis 2013; 30(5): 579-94.
[26]
Bonome T, Lee JY, Park DC, et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 2005; 65(22): 10602-12.
[27]
Zhang L, Zou W. Inhibition of integrin β1 decreases the malignancy of ovarian cancer cells and potentiates anticancer therapy via the FAK/STAT1 signaling pathway. Mol Med Rep 2015; 12(6): 7869-76.
[28]
Grisaru-Granovsky S, Salah Z, Maoz M, Pruss D, Beller U, Bar-Shavit R. Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples. Int J Cancer 2005; 113: 372-8.
[29]
Aust S, Auer K, Bachmayr-Heyda A, et al. Ambivalent role of pFAK-Y397 in serous ovarian cancer-a study of the OVCAD consortium. Mol Cancer 2014; 13: 67.
[30]
Lietha D, Cai X, Ceccarelli DF, Li Y, Schaller MD, Eck MJ. Structural basis for the autoinhibition of focal adhesion kinase. Cell 2007; 129: 1177-87.
[31]
Calalb MB, Polte TR, Hanks SK. Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinases. Mol Cell Biol 1995; 15: 954-63.
[32]
Qi JH, Claesson-Welsh L. VEGF-induced activation of phosphoinositide 3-kinase is dependent on focal adhesion kinase. Exp Cell Res 2001; 263(1): 173-82.
[33]
Boeuf FL, Houle F, Huot J. Regulation of vascular endothelial growth factor receptor 2-mediated phosphorylation of focal adhesion kinase by heat shock protein 90 and Src kinase activities. J Biol Chem 2004; 279: 39175-85.
[34]
Lim Y, Park H, Jeon J, et al. Focal adhesion kinase is negatively regulated by phosphorylation at tyrosine 407. J Biol Chem 2007; 282(14): 10398-404.
[35]
Eliceiri BP, Puente XS, Hood JD, et al. Src-mediated coupling of focal adhesion kinase to integrin αvβ5 in vascular endothelial growth factor signaling J. Cell Biol 2002; 157: 149-60.
[36]
Chang JF, Guan JL. Stimulation of cell migration by overexpression of focal adhesion kinase and its association with Src and Fyn. J Cell Sci 1996; 109(Pt 7): 1787-94.
[37]
Cary LA, Han DC, Polte TR, Hanks SK, Guan JL. Identification of p130Cas as a mediator of focal adhesion kinase-promoted cell migration. J Cell Biol 1998; 140(1): 211-21.
[38]
Ren XD, Kiosses WB, Sieg DJ, Otey CA, Schlaepfer DD, Schwartz MA. Focal adhesion kinase suppresses Rho activity to promote focal adhesion turnover. J Cell Sci 2000; 113(Pt 20): 3673-8.
[39]
Hsia DA, Mitra SK, Hauck CR, et al. Differential regulation of cell motility and invasion by FAK. J Cell Biol 2003; 160(5): 753-67.
[40]
Serrels B, Serrels A, Brunton VG, et al. Focal adhesion kinase controls actin assembly via a FERM-mediated interaction with the Arp2/3 complex. Nat Cell Biol 2007; 9(9): 1046-56.
[41]
Zhao J, Guan JL. Signal transduction by focal adhesion kinase in cancer. Cancer Metastasis Rev 2009; 28: 35-49.
[42]
Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 2009; 28(1-2): 15-33.
[43]
Zhai J, Lin H, Nie Z, et al. Direct interaction of focal adhesion kinase with p190RhoGEF. J Biol Chem 2003; 278: 24865-73.
[44]
Horiuchi A, Imai T, Wang C, et al. Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. Lab Invest 2003; 83: 861-70.
[45]
Hildebrand JD, Taylor JM, Parsons JT. An SH3 domain-containing GTPase-activating protein for Rho and Cdc42 associates with focal adhesion kinase. Mol Cell Biol 1996; 16(6): 3169-78.
[46]
Liu Y, Loijens JC, Martin KH, Karginov AV, Parsons JT. The association of ASAP1, an ADP ribosylation factor-GTPase activating protein, with focal adhesion kinase contributes to the process of focal adhesion assembly. Mol Biol Cell 2002; 13(6): 2147-56.
[47]
Wu X, Suetsugu S, Cooper LA, Takenawa T, Guan JL. Focal adhesion kinase regulation of N-WASP subcellular localization and function. J Biol Chem 2004; 279(10): 9565-76.
[48]
Kang Y, Hu W, Ivan C, et al. role of focal adhesion kinase in regulating YB–1–mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst 2013; 105(19): 1485-95.
[49]
Xie B, Zhao J, Kitagawa M, et al. Focal adhesion kinase activates Stat1 in integrin-mediated cell migration and adhesion. J Biol Chem 2001; 276: 19512-23.
[50]
Zhang L, Wang D, Jiang W, et al. Activated networking of platelet activating factor receptor and FAK/STAT1 induces malignant potential in BRCA1-mutant at-risk ovarian epithelium. Reprod Biol Endocrinol 2010; 8: 74.
[51]
Xu B, Lefringhouse J, Liu Z, et al. Inhibition of the integrin/FAK signaling axis and c-Myc synergistically disrupts ovarian cancer malignancy. Oncogenesis 2017; 6(1): e295.
[52]
Sawada K, Mitra AK, Radjabi AR, et al. Loss of E-cadherin promotes ovarian cancer metastasis via α5-integrin, which is a therapeutic target. Cancer Res 2008; 68(7): 2329-39.
[53]
Golubovskaya VM, Finch R, Zheng M, Kurenova EV, Cance WG. The 7-amino-acid site in the proline-rich region of the N-terminaldomain of p53 is involved in the interaction with FAK and is critical for p53 functioning. Biochem J 2008; 411: 151-60.
[54]
Lee JG, Ahn JH, Jin KT, Ho LJ, Choi JH. Mutant p53 promotes ovarian cancer cell adhesion to mesothelial cells via integrin β4 and Akt signals. Sci Rep 2015; 5: 12642.
[55]
Golubovskaya VM. Targeting FAK in human cancer: from finding to first clinical trials. Front Biosci 2014; 19: 687-706.
[56]
Carpten JD, Faber AL, Horn C, et al. Tucker- Kellogg, G.; Touchman, J.; Patel, K.; Mousses, S.; Bittner, M.; Schevitz, R.; Lai, M.H.; Blanchard, K.L.; Thomas, J.E. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007; 448(7152): 439-44.
[57]
Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin 2015; 65: 5-29.
[58]
Judson PL, He X, Cance WG, Van LL. Overexpression of focal adhesion kinase, a protein tyrosine kinase, in ovarian carcinoma. Cancer 1999; 86(8): 1551-6.
[59]
Gabriel B, Mildenberger S, Weisser CW, et al. Focal adhesion kinase interacts with the transcriptional coactivator FHL2 and both are overexpressed in epithelial ovarian cancer. Anticancer Res 2004; 24(2B): 921-7.
[60]
Gao M, Liu X, Sun H, Ren H, Wang L, Shen Y. Study on FAK regulation of migration of vascular endothelial cells depending upon focal adhesion proteins. J Biomed Eng 2013; 30(3): 567-71.
[61]
Li M, Hong L, Liao M, Guo G. Expression and clinical significance of focal adhesion kinase and adrenomedullin in epithelial ovarian cancer. Oncol Lett 2015; 10: 1003-7.
[62]
Halder J, Landen CN, Lutgendorf SK, et al. Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells. Clin Cancer Res 2005; 11(24): 8829-36.
[63]
Stone RL, Baggerly KA, Armaiz-Pena GN, et al. Focal adhesion kinase: An alternative focus for anti-angiogenesis therapy in ovarian cancer. Cancer Biol Ther 2014; 15(7): 919-29.
[64]
Halder J, Kamat AA, Landen CN, et al. 2006.
[65]
Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol 2002; 20(5): 1248-59.
[66]
Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin 2011; 61(3): 183-203.
[67]
Vasey PA. Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies. Br J Cancer 2003; 89(Suppl. 3): S23-8.
[68]
Holzer AK, Manorek GH, Howell SB. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol Pharmacol 2006; 70(4): 1390-4.
[69]
Chien J, Kuang R, Landen C, Shridhar V. Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment. Front Oncol 2013; 3: 251.
[70]
Bean LM, Sulzmaier FJ, Tancioni I, et al.
[71]
Rodriguez-Torres M, Allan AL. Aldehyde dehydrogenase as a marker and functional mediator of metastasis in solid tumors. Clin Exp Metastasis 2016; 33: 97-113.
[72]
Reboe, M.; Levy, A.; Dhandyuthapani, S.; Rathinavelu, A. Y15 enhances the cytotoxic profile of cisplatin, paclitaxel and vitamin e in platinum resistant ovarian cancer cells. Faseb J., 2015, 29, 785.1.
[73]
Fraser M, Leung B, Jahani-Asl A, Yan X, Thompson WE, Tsang BK. Chemoresistance in human ovarian cancer: the role of apoptotic regulators. Reprod Biol Endocrinol 2003; 1: 66.
[74]
Yusuf RZ, Duan L, Penson RT, Seiden MV. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 2003; 3: 1-19.
[75]
McGrail DJ, Khambhati NN, Qi MX, et al. Alterations in ovarian cancer cell adhesion drive taxol resistance by increasing microtubule dynamics in a FAK-dependent manner. Sci Rep 2015; 5: 9529.
[76]
Bourguignon LYW, Peyrollier K, Xia W, Gilad E. Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem 2008; 283(25): 17635-51.
[77]
Qin S, Li Y, Cao X, Du J, Huang X. NANOG regulates epithelial–mesenchymal transition and chemoresistance in ovarian cancer. Biosci Rep 2017; 37(1): BSR20160247.
[78]
Steffensen KD, Alvero AB, Yang Y, et al. Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer. J Oncol 2011; 2011: 620523.
[79]
Mitra, A.K. In: Ovarian Cancer Metastasis: A Unique Mechanism of Dissemination; Ke Xu, Ed; InTech, 2016; pp. 44-58
[80]
Mitamura T, Watari H, Wang L, et al. Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET. Oncogenesis 2013; 2(3): e40.
[81]
Kavanagh JJ. Docetaxel in the treatment of ovarian cancer. Oncology 2002; 16(6)(Suppl. 6): 73-81.
[82]
Levy AS, Khan Z, Batko S, et al. Proceedings of the AACR 107th Annual Meeting. New Orleans, LA. 2016.
[83]
Lu H, Wang L, Gao W, et al. IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells. Mol Cancer Ther 2013; 12: 2864-73.
[84]
Shi Q, Hjelmeland AB, Keir ST, et al. A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. Mol Carcinog 2007; 46(6): 488-96.
[85]
Slack-Davis JK, Martin KH, Tilghman RW, et al. Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem 2007; 282: 14845-52.
[86]
Yoon H, Choi Y-L, Song J-Y, et al. Targeted inhibition of FAK, PYK2 and BCL-XL Synergistically enhances apoptosis in ovarian clear cell carcinoma cell lines. PLoS One 2014; 9(2): e88587.
[87]
Cance WG, Kurenova E, Marlowe T, Golubovskaya V. Disrupting the scaffold to improve focal adhesion kinase-targeted cancer therapeutics. Sci Signal 2013; 6(268): pe10.
[88]
Golubovskaya VM, Ho B, Zheng M, et al. Disruption of focal adhesion kinase and p53 interaction with small molecule compound R2 reactivated p53 and blocked tumor growth. BMC Cancer 2013; 13(1): 342.
[89]
Golubovskaya VM, Figel S, Ho BT, et al. A small molecule focal adhesion kinase (FAK) inhibitor, targeting Y397 site: 1-(2-hydroxyethyl)-3, 5, 7-triaza-1-azoniatricyclo [3.3.1.13,7]decane; bromide effectively inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonogenicity and tumor growth in vivo. Carcinogenesis 2012; 33: 1004-13.
[90]
Golubovskaya VM, Nyberg C, Zheng M, et al. A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the Y397 site of focal adhesion kinase decreases tumor growth. J Med Chem 2008; 51(23): 7405-16.
[91]
Kim J-H, Skates SJ, Uede T, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002; 287(13): 1671-9.
[92]
Tancioni I, Uryu S, Sulzmaier FJ, et al. FAK inhibition disrupts a β5 integrin signaling axis controlling anchorage-independent ovarian carcinoma growth. Mol Cancer Ther 2014; 13(8): 2050-61.
[93]
Halder J, Lin YG, Merritt WM, et al. Han. L.Z.; Kim. T.J.; Lu. C.; Tari. A.M.; Bornmann. W.; Fernandez. A.; Lopez-Berestein. G.; Sood, A.K. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res 2007; 67(22): 10976-83.
[94]
Bottsford-Miller J, Sanguino A, Thanapprapasr D, et al. Proceedings of the AACR 102nd Annual Meeting. Orlando, FL. 2011.
[95]
Jones SF, Siu LL, Bendell JC, et al. A phase i study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. Invest New Drugs 2015; 33(5): 1100-7.
[96]
Patel MR, Infante JR, Moore KN, et al. Phase 1/1b study of the FAK inhibitor defactinib (VS-6063) in combination with weekly paclitaxel for advanced ovarian cancer. J Clin Oncol 2014; 32(15): 5521-1.
[97]
Soria J-C, Gan HK, Arkenau H-T, Blagden SP, Plummer R, Ranson M. Evans. T.R.J.; Zalcman. G.; Bahleda. A.; Hollebecque. A.; Lemech. C.; Dean. E.; Brown. J.; Gibson. D.; Peddareddigari. V.; Murray. S.; Nebot. N.; Mazumdar. J.; Swartz. L.; Auger. K.R.; Fleming. R.A.; Singh. R.; Millward, M. A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors. Ann Oncol 2016; 27(12): 2268-74.
